What a brutal six months it’s been for Illumina. The stock has dropped 33.6% and now trades at $89.03, rattling many ...

GRAIL, Inc. was spun off from Illumina in 2024 and offers a promising multi-cancer early detection test called Galleri. Click ...

In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of $99.00. The company’s ...

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Illumina (ILMN – Research Report), with a price target of $185.00. The company’s sha ...

The short seller’s analysis also calls into question GRAIL’s claims of the Galleri test’s positive predictive value (PPV), suggesting that the company’s comparisons to standard screening tools are ...

Diamond Hill Capital, an investment management company, released its “Mid Cap Strategy” investor letter for the first quarter ...

The stock's change was more than the S&P 500's daily gain of 0.58%. Elsewhere, the Dow saw an upswing of 0.51%, while the tech-heavy Nasdaq appreciated by 0.81%. Heading into today, shares of the ...

CLSA has an outperform rating on Bajaj Auto with the target price at Rs 10,149. Analysts said that in the Jan-March quarter, the two-wheeler major's EBITDA margin was flat on a quarterly basis and ...

Pacific Biosciences of California faces steep stock decline and financial challenges. Click here to see why PACB stock is a Sell.

This consolidation in a range is a typical price behaviour on this stock historically observed before another round of up move. A follow up move of 7-9% is likely to be unfolded post this monthly ...